



## **Prominent Canadian Cardiologist to Report Assessment of VentriPoint Heart Analysis System at International Medical Conference**

**\*\*\* Dr. Mertens will Present an Independent Evaluation of the VMS System \*\*\***

**Seattle, Washington, December 8, 2010 – VentriPoint Diagnostics** (“VentriPoint”) (TSXV: VPT) Dr. Luc Mertens will present a paper on VentriPoint’s 3D technology to monitor right heart function in children at the European Society of Cardiology conference on Thursday, December 9<sup>th</sup>.

The paper is entitled “What do we use now to assess RV function in clinical practice?” and will be presented in a symposium on “The Right Ventricle” in the Odense Room between 8:30-10:00 am at the EUROECHO 2010 Congress in Copenhagen, Denmark. Within the presentation will be the comparison of VentriPoint’s VMS™ system to the leading 3D echo software analysis program and the gold-standard MRI procedure.

**About EUROECHO 2010.** EUROECHO 2010 is the fourteenth annual meeting organized by the European Society of Cardiology with more than 3,000 participants expected to attend.

**About VentriPoint Diagnostics Ltd.** VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multibillion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS diagnostic tool and a 510(k) submission is currently being reviewed by the U.S. Federal Drug Administration.

For further information, please contact:

**VentriPoint Diagnostics Ltd.**

Dr. George Adams, CEO  
Telephone: (206) 283-0221, ext. 401  
[email: gadams@ventripoint.com](mailto:gadams@ventripoint.com)

**Howard Group Inc.**

Peter Weichler/David Burwell  
Telephone: 1.888-221-0915 or 403-221-0915  
email: [Peter@howardgroupinc.com](mailto:Peter@howardgroupinc.com)  
[Dave@howardgroupinc.com](mailto:Dave@howardgroupinc.com)

**Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release**

**FORWARD-LOOKING STATEMENTS:** The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words



"may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.